How much revenue did Gilead Sciences generate this year?
Gilead Sciences has achieved a revenue of 28.04 B USD this year.
In 2024, Gilead Sciences's sales reached 28.04 B USD, a 3.42% difference from the 27.12 B USD sales recorded in the previous year.
YEAR | REVENUE (undefined USD) | GROSS MARGIN (%) |
---|---|---|
2029e | 31.9 | 66,14 |
2028e | 31.21 | 67,60 |
2027e | 30.57 | 69,01 |
2026e | 29.47 | 71,59 |
2025e | 28.6 | 73,77 |
2024e | 28.04 | 75,23 |
2023 | 27.12 | 77,80 |
2022 | 27.28 | 79,26 |
2021 | 27.31 | 75,82 |
2020 | 24.69 | 81,48 |
2019 | 22.45 | 79,18 |
2018 | 22.13 | 78,07 |
2017 | 26.11 | 83,26 |
2016 | 30.39 | 85,98 |
2015 | 32.64 | 87,73 |
2014 | 24.89 | 84,78 |
2013 | 11.2 | 74,48 |
2012 | 9.7 | 74,52 |
2011 | 8.39 | 74,67 |
2010 | 7.95 | 76,49 |
2009 | 7.01 | 77,25 |
2008 | 5.34 | 78,88 |
2007 | 4.23 | 81,82 |
2006 | 3.03 | 85,69 |
2005 | 2.03 | 87,18 |
2004 | 1.33 | 87,40 |
In the annual report of the Gilead Sciences share (US3755581036, 885823, GILD), it breaks down its revenues into 1 segments: 1. innovative Medicines. The Gilead Sciences stock (WKN: 885823, ISIN: US3755581036, Ticker Symbol: GILD) is a leading investment for investors interested in participating in the Health Care sector.
The sales figures of Gilead Sciences originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.
Analyzing Gilead Sciences’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.
Investors often scrutinize Gilead Sciences's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.
Increases in Gilead Sciences’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.
Gilead Sciences has achieved a revenue of 28.04 B USD this year.
The revenue of Gilead Sciences has increased by 3.42% increased compared to the previous year.
The revenue of a company is an important indicator of its financial performance and attractiveness for investors.
The revenue of Gilead Sciences is influenced by various factors, including the demand for its products and services, market conditions, and prices.
Revenue is typically measured in units referring to the sale of goods and services provided by the company.
An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.
A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.
The revenue of Gilead Sciences is an important indicator of financial performance and attractiveness for investors.
A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.
Over the past 12 months, Gilead Sciences paid a dividend of 3 USD . This corresponds to a dividend yield of about 4.48 %. For the coming 12 months, Gilead Sciences is expected to pay a dividend of 0.63 USD.
The current dividend yield of Gilead Sciences is 4.48 %.
Gilead Sciences pays a quarterly dividend. This is distributed in the months of July, October, January, April.
Gilead Sciences paid dividends every year for the past 15 years.
For the upcoming 12 months, dividends amounting to 0.63 USD are expected. This corresponds to a dividend yield of 0.94 %.
Gilead Sciences is assigned to the 'Health' sector.
To receive the latest dividend of Gilead Sciences from 3/28/2024 amounting to 0.77 USD, you needed to have the stock in your portfolio before the ex-date on 3/14/2024.
The last dividend was paid out on 3/28/2024.
In the year 2023, Gilead Sciences distributed 2.92 USD as dividends.
The dividends of Gilead Sciences are distributed in USD.
The Gilead Sciences stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Our stock analysis for Gilead Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Gilead Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.